Novavax Financial Statements From 2010 to 2024
| NVV1 Stock | EUR 8.38 0.53 5.95% |
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as , as well as many indicators such as . Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
Novavax |
Novavax Company Return On Equity Analysis
Novavax's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novavax Return On Equity | -8.98 |
Most of Novavax's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novavax has a Return On Equity of -8.982. This is 62.53% lower than that of the Healthcare sector and 75.36% lower than that of the Biotechnology industry. The return on equity for all Germany stocks is notably higher than that of the company.
Novavax Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novavax's current stock value. Our valuation model uses many indicators to compare Novavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novavax competition to find correlations between indicators driving Novavax's intrinsic value. More Info.Novavax is regarded fifth in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novavax's earnings, one of the primary drivers of an investment's value.About Novavax Financial Statements
Novavax stakeholders use historical fundamental indicators, such as Novavax's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novavax investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novavax's assets and liabilities are reflected in the revenues and expenses on Novavax's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out the analysis of Novavax Correlation against competitors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.